| Literature DB >> 29951143 |
Liam Toner1, Darragh Flannery1, Hariharan Sugumar1, Michelle Ord1, Tina Lin1, David O'Donnell1.
Abstract
BACKGROUND: Cardiac resynchronization therapy (CRT) improves morbidity and mortality in patients with heart failure. Although structural remodelling correlates with improved long-term outcomes, the role of electrical remodelling is poorly understood. This study aimed to evaluate electrical remodelling following CRT using a quadripolar left ventricular (LV) lead and to correlate this with structural remodelling.Entities:
Keywords: artificial; cardiac pacing; cardiac resynchronization therapy; cardiac resynchronization therapy devices; echocardiography; heart failure
Year: 2018 PMID: 29951143 PMCID: PMC6009766 DOI: 10.1002/joa3.12063
Source DB: PubMed Journal: J Arrhythm ISSN: 1880-4276
Figure 1Plain radiographs demonstrating CRT‐defibrillator in situ with each of the 4 electrodes annotated as D1, M2, M3 and P4. Top—left anterior oblique (LAO) view and bottom—right anterior oblique (RAO)
Figure 2Intracardiac electrograms showing: A, int RV‐LV; B, LVp‐RVs
Int RV‐LV (ms) for each of the 4 electrodes (See Figure 2) at implant and at 12‐month follow‐up for a particular patient. This patient demonstrates a change in activation sequence from sequential distal to proximal to nonsequential
| LV electrode | Int RV‐LV at implant (ms) | Int RV‐LV at follow‐up (ms) |
|---|---|---|
| D1 | 170 | 107 |
| M2 | 177 | 131 |
| M3 | 178 | 145 |
| P4 | 192 | 127 |
Patient characteristics divided according to CRT response, mean ± SD
| All patients n = 40 | Responder n = 26 | Nonresponder n = 14 | |
|---|---|---|---|
| NYHA Class | 2.47 ± 0.76 | 2.71 ± 0.69 | 2.07 ± 0.73 |
| Age (years) | 65.0 ± 13.0 | 62.0 ± 13.7 | 70.4 ± 9.67 |
| Sex (%) | |||
| Male | 28 (70) | 16 (62) | 12 (86) |
| Female | 12 (30) | 10 (38) | 2 (14) |
| QRSd (ms) | 154.4 ± 8.1 | 155.0 ± 8.4 | 153.2 ± 7.8 |
| Etiology (%) | |||
| Ischaemic | 18 (45) | 9 (41) | 9 (64) |
| Nonischaemic | 22 (55) | 17 (59) | 5 (36) |
| EF Pre‐CRT (%) | 24.10 ± 6.1 | 23.81 ± 5.8 | 24.64 ± 6.6 |
| EF Post‐CRT (%) | 32.73 ± 9.0 | 36.31 ± 7.4 | 26.07 ± 7.9 |
| Change EF (%) | 8.63 ± 8.3 | 12.50 ± 7.6 | 1.43 ± 3.1 |
| LVEDD Pre (mL) | 65.75 ± 4.9 | 66.27 ± 4.9 | 64.79 ± 4.9 |
| LVEDD Post (mL) | 58.75 ± 6.4 | 56.42 ± 5.6 | 63.07 ± 5.6 |
| Change LVEDD (%) | −10.60 ± 7.6 | −14.87 ± 5.4 | −2.68 ± 3.8 |
| LVESV Pre‐CRT (mL) | 167.0 ± 62 | 173.8 ± 65 | 154.4 ± 54 |
| LVESV 12 mo (mL) | 133.6 ± 50 | 129.2 ± 49 | 141.8 ± 53 |
| Change LVESV 12 mo (%) | −19.49 ± 11 | −25.37 ± 6.7 | −8.56 ± 9.4 |
EGM values (ms), mean ± SD
| Implant | 12 mo | Reduction |
| |
|---|---|---|---|---|
| Intrinsic RV‐LV | ||||
| Mean | 121.9 ± 14.7 | 109.1 ± 15.0 | 12.8 ± 8.7 | <.01 |
| Maximum | 129.4 ± 15.5 | 116.5 ± 16.1 | 12.9 ± 10.0 | <.01 |
| RVp‐LVs | ||||
| Mean | 146.7 ± 16.7 | 135.1 ± 13.1 | 11.5 ± 8.7 | <.01 |
| Maximum | 154.2 ± 17.1 | 141.9 ± 12.7 | 12.3 ± 9.5 | <.01 |
| LVp‐RVs | ||||
| Mean | 155.7 ± 18.1 | 144.2 ± 17.1 | 11.5 ± 9.2 | <.01 |
| Maximum | 171.4 ± 20.4 | 157.8 ± 16.3 | 13.6 ± 10.4 | <.01 |
Reduction in mean EGM values (ms) from implantation to 12 mo, divided according to CRT response
| Responders | Nonresponders |
| |
|---|---|---|---|
| Intrinsic RV‐LV | 14.9 ± 8.5 | 8.9 ± 7.9 | .02 |
| RVp‐LVs | 13.1 ± 8.6 | 8.5 ± 8.3 | .06 |
| LVp‐RVs | 13.4 ± 7.4 | 9.1 ± 8.6 | .05 |
Mean ± SD.